Hanmi Pharm acquires world’s first approval of combination drug for treatment of both asthma and allergic rhinitis
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kown) announced on the 17th that it acquired commercialization approval of ‘Monterizine,’ a combination drug for patients with both asthma and allergic rhinitis(allergic rhinitis symptom relief), from the Ministry of Food and Drug Safety(MFDS).
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.